Literature DB >> 33084212

Geriatric management of older patients with multimorbidity.

Taro Kojima1, Fumihiro Mizokami2, Masahiro Akishita1.   

Abstract

Older patients tend to have multimorbidity represented by multiple chronic diseases or geriatric conditions due to aging changes of organs, which require a variety of medical management. Currently, there are no sufficient disease treatment guidelines for older people with multimorbidity, therefore physicians have difficulty managing multimorbidity, such as which diseases should be treated intensively or to what extent the conditions should be improved. Furthermore, there are other points to be considered when initiating the treatment of diseases. For example, physicians must assess physical function. Some people have no difficulty with ambulation, but some are bedridden and have difficulty getting up on their own. As there are differences in disease severity, comorbid conditions and life expectancy, there should be differences in deciding treatment and prescribing drugs. It may be necessary to change the option for treatment depending on cognitive function, the living environment and the care environment, using comprehensive geriatric assessments. In addition, when treating multimorbidity, patients tend to have polypharmacy, which is a risk for adverse drug events. Because of this, it is necessary to consider dose reduction and drug discontinuation in patients with polypharmacy. Because of the global increase in older patients with multimorbidity, developing an essential method for managing multimorbidity is an urgent issue. More research and practices are necessary to achieve high-quality care in patients with multimorbidity. Geriatr Gerontol Int 2020; 20: 1105-1111.
© 2020 Japan Geriatrics Society.

Entities:  

Keywords:  frailty; multimorbidity; polypharmacy

Year:  2020        PMID: 33084212     DOI: 10.1111/ggi.14065

Source DB:  PubMed          Journal:  Geriatr Gerontol Int        ISSN: 1447-0594            Impact factor:   2.730


  7 in total

1.  Perceived declining physical and cognitive fitness during the COVID-19 state of emergency among community-dwelling Japanese old-old adults.

Authors:  Hyuma Makizako; Yuki Nakai; Daijo Shiratsuchi; Tomomi Akanuma; Kaori Yokoyama; Yuriko Matsuzaki-Kihara; Hiroto Yoshida
Journal:  Geriatr Gerontol Int       Date:  2021-02-11       Impact factor: 2.730

2.  Evaluation of changes in prescription among Japanese elderly patients before and after transition to home care.

Authors:  Shoichi Masumoto; Mikiya Sato; Tomotsugu Yamakawa; Shuhei Hamada; Takashi Inaba; Yoshihiro Kataoka; Sachiko Ozone; Shoji Yokoya; Jun Hamano
Journal:  J Gen Fam Med       Date:  2021-11-08

3.  Prevalence of constipation and use of laxatives, and association with risk factors among older patients during hospitalization: a cross sectional study.

Authors:  Hanne Konradsen; Veronica Lundberg; Jan Florin; Anne-Marie Boström
Journal:  BMC Gastroenterol       Date:  2022-03-08       Impact factor: 3.067

Review 4.  Management of chemotherapy dose intensity for metastatic colorectal cancer.

Authors:  Xuelei Chu; Peng Xue; Shijie Zhu
Journal:  Oncol Lett       Date:  2022-03-11       Impact factor: 2.967

5.  Improving individualized prescription in patients with multimorbidity through medication review.

Authors:  Núria Molist-Brunet; Daniel Sevilla-Sánchez; Emma Puigoriol-Juvanteny; Matilde Barneto-Soto; Javier González-Bueno; Joan Espaulella-Panicot
Journal:  BMC Geriatr       Date:  2022-05-12       Impact factor: 4.070

6.  Association between preoperative hypokalemia and postoperative complications in elderly patients: a retrospective study.

Authors:  Tiantian Chu; Zongfang Wu; Aijun Xu
Journal:  BMC Geriatr       Date:  2022-09-12       Impact factor: 4.070

7.  Prevalence of Polypharmacy, Hyperpolypharmacy and Potentially Inappropriate Medication Use in Older Adults in India: A Systematic Review and Meta-Analysis.

Authors:  Akshaya S Bhagavathula; Kota Vidyasagar; Manik Chhabra; Muhammed Rashid; Rishabh Sharma; Deepak K Bandari; Daniela Fialova
Journal:  Front Pharmacol       Date:  2021-05-19       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.